| Swedish Orphan Biovitrum–ADC Therapeutics: loncastuximab tesirine-lpyl, 202207– license excl $55m upfront + $710m milestones outside US+China+SG+JP |
2022-07-08 |
| Biosyntia–ECBF: investment, 202207 financing round Series B totalling €11.5m incl new + lead investor ECBF |
2022-07-07 |
| Biosyntia–SEVERAL: investment, 202207 financing round Series B €11.5m led by new investor ECBF |
2022-07-07 |
| Aurobac Therapeutics–Boehringer: investment, 202207 launch of €40m joint venture Aurobac incl €30m from lead investor Boehringer Ingelheim |
2022-07-06 |
| BeiGene–InnoRNA: mRNA therapies, 202207– collab strategic r+d ww using InnoRNA LNP-based delivery technology with ww rights for BeiGene |
2022-07-06 |
| Boehringer–Evotec: investment, 202207 launch of €40m joint venture Aurobac incl €5m from co-investor Evotec |
2022-07-06 |
| Boehringer–Mérieux: investment, 202207 launch of €40m joint venture Aurobac incl €5m from co-investor bioMérieux |
2022-07-06 |
| Life Science Valley–Lower Saxony (govt): grant, 202207–202412 project grant funding €5m with €2m for business incubator + €3m directly for start-ups |
2022-07-01 |
| Pepscan–Biosynth Carbosynth: investment, 202206 acquisition of Pepscan by Biosynth Carbosynth |
2022-06-30 |
| Molzym–OTHER: investment, 202206 investment 2-digit €m from large single family office |
2022-06-29 |
| Green Generation–SEVERAL: investment, 202206 fund launched with €100m raised |
2022-06-28 |
| Verve Capital Partners–SEVERAL: investment, 202206 1st CHF45m closing of Verve Venture Fund I |
2022-06-24 |
| F-Star–Sino Biopharm: investment, 202206– acquisition $161m cash tender offer by invoX Pharma at $7.12/share ANNOUNCED |
2022-06-23 |
| Ningaloo Biosystems–North Rhine-Westphalia (govt): investment, 202206 pre-seed financing round incl investor NRW.Bank |
2022-06-22 |
| Ningaloo Biosystems–OTHER: investment, 202206 pre-seed financing round incl team of business angels |
2022-06-22 |
| Ningaloo Biosystems–SEVERAL: investment, 202206 pre-seed financing round with business angels + NRW.Bank |
2022-06-22 |
| SPT Labtech–EQT: investment, 202206– acquisition £650m of SPT Labtech by EQT IX Fund from Battery Ventures |
2022-06-22 |
| Carma Fund–EU (govt): investment, 202206 first closing totalling €47m of Carma Fund I incl investor EIF |
2022-06-21 |
| Carma Fund–Evotec: investment, 202206 first closing totalling €47m of Carma Fund I incl investor Evotec SE |
2022-06-21 |
| Carma Fund–Life Science-Stiftung: investment, 202206 first closing totalling €47m of Carma Fund I incl investor Ascenion GmbH |
2022-06-21 |
| Carma Fund–Orbit Fund Boutique: legal services, 202206 supply service legal advise on fund structure |
2022-06-21 |
| Carma Fund–SEVERAL: investment, 202206 first closing €47m of Carma Fund I with target size of €60m |
2022-06-21 |
| Carma Fund–Univ Frankfurt: investment, 202206 first closing totalling €47m of Carma Fund I incl investor Innovectis GmbH |
2022-06-21 |
| Novartis–Precision BioSciences: gene therapy, 202206– collab ww $50m upfront + $1.4b milestones + royalties using ARCUS platform to develop therapies |
2022-06-21 |
| Precision BioSciences–Novartis: investment, 202206 equity purchase $25m at $2.01/share in connection with collaboration |
2022-06-21 |
| Kranus Health–A Round Capital: investment, 202206 financing round Series A totalling >$6.5m incl existing + co-investor A Round Capital |
2022-06-20 |
| Kranus Health–High-Tech Gründerfonds: investment, 202206 financing round Series A totalling >$6.5m incl existing + co-investor HTGF |
2022-06-20 |
| Kranus Health–Karista: investment, 202206 financing round Series A totalling >$6.5m incl lead investor Karista |
2022-06-20 |
| Kranus Health–Peak Pride: investment, 202206 financing round Series A totalling >$6.5m incl co-investor Peak Pride |
2022-06-20 |
| Kranus Health–PERSON: investment, 202206 financing round Series A totalling >$6.5m incl co-investor Ehsan Khaljani |
2022-06-20 |
| Kranus Health–PERSON: investment, 202206 financing round Series A totalling >$6.5m incl co-investor Florian Brand |
2022-06-20 |
| Kranus Health–Saarbruecker21: investment, 202206 financing round Series A totalling >$6.5m incl co-investor business angel group Saarbruecker21 |
2022-06-20 |
| Kranus Health–SEVERAL: investment, 202206 financing round Series A >$6.5m led by Karista |
2022-06-20 |
| Valneva–Pfizer: investment, 202206 equity investment via capital increase €90.5m (representing 8.1% if capital) at €9.49/share |
2022-06-20 |
| Ymmunobio–Yumab: cancer antibody drug, 202206– collab €na optimisation of CEACAM antibodies by Yumab |
2022-06-16 |
| Dren Bio–HBM: investment, 202206 financing round Series B totalling $65m incl co-lead investor HBM Healthcare Investments |
2022-06-14 |
| Dren Bio–SEVERAL: investment, 202206 financing round Series B $65m led by Aisling Capital + HBM Healthcare Investments |
2022-06-14 |
| High-Tech Gründerfonds–SEVERAL: investment, 202206 1st closing of HTGF IV at more than €400m incl BMWK + KfW Capital |
2022-06-14 |
| JnJ–Evotec: drug discovery services, 202206– collab discover novel mode of action drugs using TargetAlloMod platforms for Janssen Pharmaceutica |
2022-06-14 |
| ImCheck Therapeutics–Bellevue: investment, 202206 financing round Series C totalling €80m incl existing + co-investor Pureos Bioventures |
2022-06-13 |
| ImCheck Therapeutics–Boehringer: investment, 202206 financing round Series C totalling €80m incl existing + co-investor BIVF |
2022-06-13 |
| ImCheck Therapeutics–Earlybird: investment, 202206 financing round Series C totalling €80m incl new + co-lead investor Earlybird |
2022-06-13 |
| ImCheck Therapeutics–SEVERAL: investment, 202206 financing round Series C €80m co-led by new investors Earlybird + Andera Partners |
2022-06-13 |
| ImCheck Therapeutics–Wellington Partners: investment, 202206 financing round Series C totalling €80m incl existing + co-investor Wellington Partners |
2022-06-13 |
| ModuVision–Knauer: investment, 202206 acquisition of ModuVision by Knauer |
2022-06-13 |
| Forbion–SEVERAL: investment, 202206 first close €470m of Forbion Growth Opportunities Fund II with target size of €600m hard cap |
2022-06-09 |
| Peptone–Novartis: investment, 202206 financing round Series A totalling $40m incl existing + co-investor dRX Capital |
2022-06-09 |
| Peptone–Nvidia: AI-based drug discovery, 202206 collab incl use of Nvidia DGX A100 supercomputer to run Peptone’s algorithmic engine |
2022-06-09 |
| Peptone–SEVERAL: investment, 202206 financing round Series A $40m led by F-Prime + Bessemer Venture Partners |
2022-06-09 |
| Relation Therapeutics–PERSON: investment, 202206 seed financing round totalling $25m incl co-investor Peer Schatz |
2022-06-09 |
| Relation Therapeutics–SEVERAL: investment, 202206 seed financing round $25m co-led by DCVC + Magnetic Ventures |
2022-06-09 |
| Ariceum Therapeutics–Bellevue: investment, 202206 financing round Series A totalling €25m incl co-investor Pureos Bioventures |
2022-06-08 |
| Ariceum Therapeutics–EQT: investment, 202206 financing round Series A totalling €25m incl co-founding + co-lead investor EQT Life Sciences |
2022-06-08 |
| Ariceum Therapeutics–Odlander Fredrikson: investment, 202206 financing round Series A totalling €25m incl co-founding + co-lead investor HealthCap |
2022-06-08 |
| Ariceum Therapeutics–Optimum Strategic Communications: public relations, 202206 service existent by Optimum |
2022-06-08 |
| Ariceum Therapeutics–SEVERAL: investment, 202206 financing round Series A €25m co-led by HealthCap + EQT Life Sciences |
2022-06-08 |
| BioVersys–SEVERAL: investment, 202206 financing round Series C first closing CHF24.2m from existing + new investors |
2022-06-08 |
| Frame Cancer Therapeutics–CureVac: investment, 202206 acquisition in shares €32m with €16m upfront + €16m milestones |
2022-06-08 |
| Mineralys Therapeutics–Andera Partners: investment, 202206 financing round Series B totalling $118m incl new + co-lead investor BioDiscovery 6 fund |
2022-06-08 |
| Mineralys Therapeutics–RA Capital: investment, 202206 financing round Series B totalling $118m incl new + co-lead investor RA Capital Management |
2022-06-08 |
| Mineralys Therapeutics–SEVERAL: investment, 202206 financing round Series B $118m led by RA Capital + Andera Partners |
2022-06-08 |
| Immatics–Editas Medicine: CRISPR technology, 202206– collab strategic research + license €na for use of CRISPR with ACTallo cell therapy platform |
2022-06-07 |
| ImmunOs Therapeutics–BioMedPartners: investment, 202206 financing round Series B totalling $74m incl existing + co-investor BioMedPartners |
2022-06-07 |
| ImmunOs Therapeutics–Fiscus Financial: investment, 202206 financing round Series B totalling $74m incl new + co-investor Fiscus Financial |
2022-06-07 |
| ImmunOs Therapeutics–Gimv: investment, 202206 financing round Series B totalling $74m incl new + co-lead investor Gimv |
2022-06-07 |
| ImmunOs Therapeutics–GL Capital: investment, 202206 financing round Series B totalling $74m incl new + co-investor GL Capital |
2022-06-07 |
| ImmunOs Therapeutics–Lightspeed Venture Partners: investment, 202206 financing round Series B totalling $74m incl new + co-lead investor Lightspeed VP |
2022-06-07 |
| ImmunOs Therapeutics–Mission BioCapital: investment, 202206 financing round Series B totalling $74m incl new + co-investor Mission BioCapital |
2022-06-07 |
| ImmunOs Therapeutics–Peak6 Strategic Capital: investment, 202206 financing round Series B totalling $74m incl new + co-investor Peak6 |
2022-06-07 |
| ImmunOs Therapeutics–Pfizer: investment, 202206 financing round Series B totalling $74m incl existing + co-investor Pfizer Ventures |
2022-06-07 |
| ImmunOs Therapeutics–Samsara BioCapital: investment, 202206 financing round Series B totalling $74m incl new + co-lead investor Samsara BioCapital |
2022-06-07 |
| ImmunOs Therapeutics–Schroders: investment, 202206 financing round Series B totalling $74m incl existing + co-investor Schroder Adveq |
2022-06-07 |
| ImmunOs Therapeutics–SEVERAL: investment, 202206 financing round Series B $74m led by Samsara BioCapital + Lightspeed VP + Gimv |
2022-06-07 |
| Invasight–Avanteca Partners: investment, 202206 seed financing round totalling CHF4.5m incl co-investor Avanteca Partners |
2022-06-07 |
| Invasight–High-Tech Gründerfonds: investment, 202206 seed financing round totalling CHF4.5m incl co-investor HTGF |
2022-06-07 |
| Invasight–Occident: investment, 202206 seed financing round totalling CHF4.5m incl lead investor Occident |
2022-06-07 |
| Invasight–OTHER: investment, 202206 seed financing round totalling CHF4.5m incl angel investors |
2022-06-07 |
| Invasight–SEVERAL: investment, 202206 seed financing round CHF4.5m led by Occident |
2022-06-07 |
| Invasight–Univ Basel: investment, 202206 seed financing round totalling CHF4.5m incl co-lead investor JFG Life Sciences Foundation |
2022-06-07 |
| Invasight–Verve Capital Partners: investment, 202206 seed financing round totalling CHF4.5m incl co-investor Verve Ventures |
2022-06-07 |
| Invasight–Wille Finance: investment, 202206 seed financing round totalling CHF4.5m incl co-investor Wille Finance AG |
2022-06-07 |
| Invasight–Zürcher Kantonalbank: investment, 202206 seed financing round totalling CHF4.5m incl co-investor ZKB |
2022-06-07 |
| BMS–Immatics: cancer immunotherapy, 202201– collab strategic alliance expansion $60m upfront + $700 milestones per programme using ACTallo platform |
2022-06-02 |
| Merck (DE)–Proxygen: molecular glue degraders, 202206– strategic multi-year collab + license agreem up to €495m plus royalties |
2022-06-02 |
| Upstream Bio–HBM: investment, 202206 financing round Series A totalling $200m incl co-investor HBM Healthcare Investments |
2022-06-02 |
| Upstream Bio–SEVERAL: investment, 202206 financing round Series A $200m co-led by OrbiMed + Maruho Co Ltd |
2022-06-02 |
| Agilent–Mettler-Toledo: lab automation, –202206 collab developm + product integration automated + digitalised sample prep for LC/GC workflow |
2022-06-01 |
| Roche–Repare Therapeutics: ATR inhibitor, 202206– 202402 ww license + collab camonsertib $125m upfront + $1.2b milestones + royalties TERMINATED 2/24 |
2022-06-01 |
| Firmenich–DSM: investment, 202205– merger with former DMS owners holding 65.5% + Firmenich owners receiving 34.5% plus €3.5b in cash ANNOUNCED |
2022-05-31 |
| Minoryx–SEVERAL: credit, 202205 complementary bank debt to Series C financing round (both tog totalling €51m) |
2022-05-31 |
| Minoryx–SEVERAL: investment, 202205 financing round Series C (incl complementary bank totalling €51m) led by Columbus VP + Caixa Capital Risc |
2022-05-31 |
| Partex–Merck (DE): MetAP2 inhibitor, 202205– license to M8891 to Cureteq for AI-based development by Oncoteq from Merck KGaA |
2022-05-30 |
| Rigenerand–Evotec: investment, 202205–202207 acquisition 100% for €23m |
2022-05-30 |
| Rigenerand–Xyence Capital: investment, 202205 existent Xyence is majority shareholder at time of sale of Rigenerand to Evotec |
2022-05-30 |
| Irubis–EU (govt): grant, 202005– grant €1.3m from EIC Accelerator Pilot Programme |
2022-05-26 |
| Aalto Bio Reagents–Biosynth Carbosynth: investment, 202205 acquisition of Aalto by Biosynth Carbosynth |
2022-05-25 |
| CureVac–myNEO: drug target discovery, 202205– collab research + option agreem antigen targets for mRNA cancer vaccines |
2022-05-25 |
| Alithea Genomics–Novalis Biotech: investment, 202205 seed financing round totalling CHF1m incl lead investor Novalis Biotech Acceleration Fund |
2022-05-24 |
| Alithea Genomics–OTHER: investment, 202205 seed financing round totalling CHF1m incl Swiss-based private investors as co-investors |
2022-05-24 |
| Alithea Genomics–SEVERAL: investment, 202205 seed financing round CHF1m led by Novalis Biotech Acceleration Fund |
2022-05-24 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo.svg){kind=logo}
1 2 3 ... 11 12 13 ... 35 36 37 
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
